There’s a sample I’ve discovered to acknowledge over time. It begins with whispers. Quiet accumulation. Cash transferring earlier than the gang notices.
Again in 2022… I began telling my readers to get into gold and treasured metals.
Right here’s what I noticed…
Central banks all over the world had been shopping for bullion. The largest kahuna of all of them, the U.S., was piling on debt.
These two components alone had been sufficient to ignite extra shopping for forward.
Quick-forward to 2026… I nailed it. Gold topped $4,635 an oz. (up 72% yr over yr), silver hit $92 an oz. (up 200% in a yr) – validating these early indicators.
Now I’m telling you to purchase shares within the biotech sector.
Right here’s why…
Large pharma is sitting on a patent cliff that’s about to grow to be a income disaster.
Between 2026 and 2030, the sector faces a “super-cliff” with $180 billion to $236 billion in annual income in danger from patent expirations.
I’m speaking about blockbusters like Merck’s Keytruda ($25 billion in annual gross sales), expiring in 2028… Pfizer’s Ibrance ($6.4 billion), going off patent in 2027… and dozens extra.
They’ve to exchange that income – and quick. That urgency is driving an M&A explosion.
Biotech M&A exploded 73% to $228 billion in 2025 – and analysts predict greater than 20 offers over $1 billion every in 2026.
Simply take a look at what occurred with weight problems drugmaker Metsera final yr.
When Pfizer and Novo Nordisk obtained right into a bidding conflict over the corporate, Metsera’s shares doubled as the worth escalated from preliminary bids of $4.9 billion to Pfizer’s profitable $10 billion provide.
Or take Revolution Medicines (RVMD), which jumped 29% on Merck takeover rumors, pushing its market cap close to $20 billion.
These aren’t small strikes. It is a sector the place triple-digit positive aspects are the norm throughout takeovers.
Within the Struggle Room, we’ve already cleaned up twice previously two years on State Avenue SPDR S&P Biotech ETF (XBI), which surged 36% in 2025 alone.
However that’s not the place the massive cash shall be made.
The massive cash will come from particular person shares that nobody is taking a look at… nobody however huge pharma.
It’s a sector ripe with alternatives.
YOUR ACTION PLAN
Two under-$10 shares are on my radar now… and certainly one of them is underneath $5.
Each have large potential as standalone corporations or takeover targets.
A 3rd inventory is a biotech play that makes use of AI to develop medication.
That’s simply three out of many alternatives on this sector.
These performs are nonetheless comparatively unknown to most individuals, however to not Large Pharma.
They’re arguably probably the most educated about which corporations have potential and which don’t.
And so they have the deep pockets to make a number of bets. With $1.2 trillion in acquisition capability burning a gap of their stability sheets and pipelines that desperately want replenishing, they’re prepared to put in writing huge checks.
The information backs up what I’m seeing. There have been 129 offers value $138 billion in biopharma alone final yr, with the October-November interval seeing a $36 billion surge.
The feeding frenzy is simply getting began.
Don’t miss this like the gang missed gold at $1,800. The biotech takeover wave is right here.
 |
FUN FACT FRIDAY
In 1886, Atlanta pharmacist John Pemberton created “Coca-Cola” as a mind tonic and headache treatment, mixing coca leaf extract (with about 9 mg of cocaine per glass initially) and kola nut extract (containing caffeine).
He bought it at soda fountains for illnesses like morphine dependancy, indigestion, and nerve points. It was marketed as a “precious mind tonic” earlier than changing into the world’s most iconic delicate drink.